ReviewClinical and experimental nephrology2017
Mineral metabolism and cardiovascular disease in CKD.
Review in Clinical and experimental nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- Safety of Low-calcium Dialysate and its Effects on Coronary Artery Calcification in Patients Undergoing Maintenance Hemodialysis.Scientific reports · 2018Trial
- Data-driven cluster analysis identifies three clinical phenotypes in hemodialysis patients.Renal failure · 2025Article
- Comparative analysis of plasma BNP and NT-proBNP levels, and NT-proBNP/BNP ratio in patients with chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Chronic kidney disease and valvular heart disease: State of the art.Physiological reports · 2025Review
- Recurrent Inflammatory State due to Severe Periarticular Calcifications in a Patient on Hemodialysis: A Case Report.Clinical case reports · 2025Article
- Impact of Kidney Function on Physiological Assessment of Coronary Circulation.Reviews in cardiovascular medicine · 2024Article
- Rethinking Mitral Annular Calcification and Its Clinical Significance: From Passive Process to Active Pathology.Journal of personalized medicine · 2024Review
- Framework of Guidelines for Management of CKD in Asia.Kidney international reports · 2024Article
- Phosphate and Coronary Artery Disease in Patients with Chronic Kidney Disease.Journal of atherosclerosis and thrombosis · 2024Review
- Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism.World journal of cardiology · 2022Article
- Effects of pharmacological inhibition of the sodium-dependent phosphate cotransporter 2b (NPT2b) on intestinal phosphate absorption in mouse and rat models.Pharmacology research & perspectives · 2022Article
- Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy.Journal of the Endocrine Society · 2022Article
- Valvular Heart Disease in Patients with Chronic Kidney Disease.European cardiology · 2022Review
- Association between Serum Phosphate Levels and the Development of Aortic Stenosis in Patients Undergoing Hemodialysis.Journal of clinical medicine · 2021Article
- Dental caries status is associated with arteriosclerosis in patients on hemodialysis.Clinical and experimental nephrology · 2021Article
- Phosphate binders usage, patients knowledge, and adherence. A cross-sectional study in 4 centers at Qassim, Saudi Arabia.Saudi medical journal · 2020Article
- Factors affecting the relationship between ionized and corrected calcium levels in peritoneal dialysis patients: a retrospective cross-sectional study.BMC nephrology · 2020Article
- Review
- Current Management Strategies of Chronic Kidney Disease in Resource-Limited Countries.International journal of nephrology and renovascular disease · 2020Review
- Effect of kidney donation on bone mineral metabolism.PloS one · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mineral bone disorder of CKD, called Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), has a major role in the etiology and progression of cardiovascular disease in CKD patients. Since the main emphasis in CKD-MBD is on three categories (bone abnormalities, laboratory abnormalities, and vascular calcifications), we have routinely accepted ectopic cardiovascular calcifications as a central risk factor in the pathophysiology of CKD-MBD for cardiac events. However, recent compelling evidence suggests that some CKD-MBD-specific factors other than vascular calcification might contribute to the onset of cardiovascular disease. Most notable is fibroblast growth factor-23 (FGF23), which is thought to be independently associated with cardiac remodeling. Slow progression of cardiac disorders, such as vascular calcification and cardiac remodeling, characterizes cardiac disease due to CKD-MBD. In contrast, fatal arrhythmia may be induced when QT prolongation occurs with CKD-MBD treatment, such as with lower Ca dialysate or the use of calcimimetics. Sudden onset of fatal cardiac events, such as heart failure and sudden cardiac death, due to fatal arrhythmia would be another distinctive phenomenon of CKD-MBD. This may be defined as CKD-MBD-specific cardiac complex syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.